ONESOURCE.NS
ONESOURCE.NS
INE013P01021
ONESOURCE SPECL PHARMA L
Loading chart...

Company Profile

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed pens, and autoinjectors and self-administration platforms; sterile injectables; soft gelatin capsules; and biologics solutions for recombinant proteins, monoclonal antibodies and biosimilars, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Related stocks

CONCORDBIO.NS
CONCORDBIO.NS • India
CONCORD BIOTECH LIMITED
1,361.4 INR
1.47B USD 1Y -14.4%
SUPRIYA.NS
SUPRIYA.NS • India
SUPRIYA LIFESCIENCE LTD
847.65 INR
704.91M USD 1Y +17.7%
PYC.AX
PYC.AX • Australia
PYC THERAP FPO [PYC]
2.45 AUD
1.68B USD 1Y +109.4%
MSB.AX
MSB.AX • Australia
MESOBLAST FPO [MSB]
2 AUD
1.81B USD 1Y -32.2%
NEU.AX
NEU.AX • Australia
NEUREN FPO NZ [NEU]
20.2 AUD
1.79B USD 1Y -5.3%
301207.SZ
301207.SZ • China
HUALAN VAC
19.88 CNY
1.79B USD 1Y +14.6%
002287.SZ
002287.SZ • China
CHEEZHENGTTM
19.56 CNY
1.67B USD 1Y -24.9%
300204.SZ
300204.SZ • China
STAIDSON BIO
20.66 CNY
1.67B USD 1Y -38.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende